Rebalix
Logo AmundiAmundi · sheet of 10 September 2026
ETF sheet · official issuer and register data

Amundi Nasdaq-100 Target Income UCITS ETF Dist

NSDT · LU3299677438 · class UCITS ETF Dist · USD · domicile Luxembourg
Equity · United States · Large capSFDR art. 6
Index tracked: Nasdaq-100 8% Income Target Index
TER
0.40%+ trans. 0.00%
Fund size
27 m EUR
Tracking difference
not computable
🇮🇹 tax rate
26.00%equity
Replication
Synthetic (swap)
Income
Distributingquarterly
Launch 5 May 2026 · costs from the KID as of 2 Sept 2026 · 26 securities held · 9 venues (ESMA register)

The fund’s objective — in the issuer’s words

From the Key Information Document (KID) · 4 Aug 2026
This Sub-Fund is passively managed. The objective of this Sub-Fund is to track the performance of Nasdaq – 100 8% Income Target Index (the "Index") and to minimize the tracking error between the net asset value of the Sub-Fund and the performance of the Index. The anticipated level of the tracking error, under normal market conditions, is indicated in the prospectus of the Sub-Fund. The Index is a net total return index, meaning that dividends net of tax paid by the index constituents are included in the Index return. The Index measures the performance…

Performance since series start (in euro) — base 100

5 May 20268 Sept 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
10999106
High 109 (30 Jun 2026) · low 99 (29 Jul 2026) · last 106. Past performance is not indicative of future results.

Returns in euro

1 yearseries too young
3 yearsseries too young
5 yearsseries too young
10 yearsseries too young
Since series start+5.7%

Risk · 1 / 3 / 5 years

Volatility (ann.)
Max drawdown
Sharpe
Sortino
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · NSDT · LU32996774381
RebalixNSDT · LU3299677438 · sheet of 10 September 2026

Tracking difference — year by year

Fund minus index, complete calendar years
Not honestly computable: index series not published by the issuer

Distributions · per share, in USD

Frequency: quarterly · last 12 months: 0.055 USD (1.06% of NAV) · 2 months of history: not a full year · last ex-date 1 Jul 2026
YearPaymentsTotal (USD)
202610.055

Holdings

Synthetic replication: top positions of the substitute basket (swap collateral), not the fund’s exposure · 1 Sept 2026 · 26 securities · top-10 weight = 58.9%
Top holdingsWeight
META PLATFORMS INC-CLASS A8.7%
COPART INC8.5%
CARIS LIFE SCIENCES INC8.0%
MICROCHIP TECHNOLOGY INC7.3%
VERIZON COMMUNICATIONS INC4.5%
ELI LILLY & CO4.5%
SANDISK CORP4.4%
UNITED THERAPEUTICS CORP4.4%
ABBVIE INC4.3%
CRH PLC NYSE4.2%

Listing venues

ESMA register (FIRDS) and official exchange lists
NSDT · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Euronext Paris, Tradegate Exchange, Xetra (Deutsche Börse)
+ 6 unmapped venues (MTF, RFQ, professional)

Official documents

Clickable links in the PDF
KID · www.amundietf.it/pdfDocuments/kid-priips/LU3299677438/ENG/NLD
Prospectus · www.amundietf.it/pdfDocuments/prospectus/LU3299677438/ENG/GBR
The live sheet, always up to date
rebalix.com/en/etf/LU3299677438
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.

Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.

Rebalix · NSDT · LU32996774382